Attralus Receives FDA Fast Track Designation for AL Amyloidosis Treatment

Attralus, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead pan-amyloid removal candidate, zamubafusp alfa (AT-02), for the treatment of light chain (AL)-associated amyloidosis. This designation aims to facilitate and expedite the development and review of drugs addressing serious conditions with unmet medical needs.